KRAS and colorectal carcinoma: Regarding PDAC patients, only 7 were enrolled in the trial, of which three displayed partial response and four showed stable disease, with a resulting ORR of 43%.388 Additionally, divarasib is currently being evaluated in this Phase Ib trial in combination with cetuximab in patients with KRAS G12C CRC.